---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001189"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:19:29.989632+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B

## Summary
- Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.
- Base business (ex-Nevro) Q4 revenue $723.3M, +10.0% YoY, led by US Spine.
- Enabling Technologies delivered best quarterly revenue performance to date.
- FY2026 revenue guidance $3.18B-$3.22B; non-GAAP EPS guidance $4.30-$4.40.
- Final Q4/FY2025 results expected on February 24, 2026 after market close.

## SEC filing metadata
- accession: 0001628280-26-001189
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/0001628280-26-001189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000162828026001189/gmed-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001189
- JSON: https://secwatch.observer/filing/0001628280-26-001189.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.